{"id":12464,"date":"2022-11-19T12:44:48","date_gmt":"2022-11-19T12:44:48","guid":{"rendered":"https:\/\/dailytalks.org\/?p=12464"},"modified":"2022-11-19T12:44:48","modified_gmt":"2022-11-19T12:44:48","slug":"imfinzi-plus-chemotherapy-recommended-for-approval-in-eu-by-chmp-as-first-immunotherapy-regimen-for-advanced-biliary-tract-cancer-mirage-news","status":"publish","type":"post","link":"https:\/\/dailytalks.org\/?p=12464","title":{"rendered":"Imfinzi plus chemotherapy recommended for approval in EU by CHMP as first immunotherapy regimen for advanced biliary tract cancer | Mirage News"},"content":{"rendered":"<p>AstraZeneca\u2019s Imfinzi (durvalumab) has been recommended for marketing authorisation in the European Union (EU) for the 1st-line treatment of adult patients with unresectable or metastatic biliary tract cancer (BTC) in combination with chemotherapy (gemcitabine plus cisplatin). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency based its positive opinion on\u2026<br \/><a href=\"https:\/\/uspolitics.einnews.com:443\/article\/601163127\/live\" class=\"button purchase\" rel=\"nofollow noopener\" target=\"_blank\">Read More<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca\u2019s Imfinzi (durvalumab) has been recommended for marketing authorisation in the European Union (EU) for<\/p>\n","protected":false},"author":1,"featured_media":12465,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[],"class_list":["post-12464","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-europe"],"featured_image_urls":{"full":["https:\/\/dailytalks.org\/wp-content\/uploads\/2022\/11\/12464-imfinzi-plus-chemotherapy-recommended-for-approval-in-eu-by-chmp-as-first-immunotherapy-regimen-for-advanced-biliary-tract-cancer-mirage-news.jpg",640,480,false],"thumbnail":["https:\/\/dailytalks.org\/wp-content\/uploads\/2022\/11\/12464-imfinzi-plus-chemotherapy-recommended-for-approval-in-eu-by-chmp-as-first-immunotherapy-regimen-for-advanced-biliary-tract-cancer-mirage-news-150x150.jpg",150,150,true],"medium":["https:\/\/dailytalks.org\/wp-content\/uploads\/2022\/11\/12464-imfinzi-plus-chemotherapy-recommended-for-approval-in-eu-by-chmp-as-first-immunotherapy-regimen-for-advanced-biliary-tract-cancer-mirage-news-300x225.jpg",300,225,true],"medium_large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2022\/11\/12464-imfinzi-plus-chemotherapy-recommended-for-approval-in-eu-by-chmp-as-first-immunotherapy-regimen-for-advanced-biliary-tract-cancer-mirage-news.jpg",640,480,false],"large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2022\/11\/12464-imfinzi-plus-chemotherapy-recommended-for-approval-in-eu-by-chmp-as-first-immunotherapy-regimen-for-advanced-biliary-tract-cancer-mirage-news.jpg",640,480,false],"1536x1536":["https:\/\/dailytalks.org\/wp-content\/uploads\/2022\/11\/12464-imfinzi-plus-chemotherapy-recommended-for-approval-in-eu-by-chmp-as-first-immunotherapy-regimen-for-advanced-biliary-tract-cancer-mirage-news.jpg",640,480,false],"2048x2048":["https:\/\/dailytalks.org\/wp-content\/uploads\/2022\/11\/12464-imfinzi-plus-chemotherapy-recommended-for-approval-in-eu-by-chmp-as-first-immunotherapy-regimen-for-advanced-biliary-tract-cancer-mirage-news.jpg",640,480,false],"chromenews-featured":["https:\/\/dailytalks.org\/wp-content\/uploads\/2022\/11\/12464-imfinzi-plus-chemotherapy-recommended-for-approval-in-eu-by-chmp-as-first-immunotherapy-regimen-for-advanced-biliary-tract-cancer-mirage-news.jpg",640,480,false],"chromenews-large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2022\/11\/12464-imfinzi-plus-chemotherapy-recommended-for-approval-in-eu-by-chmp-as-first-immunotherapy-regimen-for-advanced-biliary-tract-cancer-mirage-news.jpg",640,480,false],"chromenews-medium":["https:\/\/dailytalks.org\/wp-content\/uploads\/2022\/11\/12464-imfinzi-plus-chemotherapy-recommended-for-approval-in-eu-by-chmp-as-first-immunotherapy-regimen-for-advanced-biliary-tract-cancer-mirage-news-590x410.jpg",590,410,true]},"author_info":{"display_name":"Jonathan Jeriah","author_link":"https:\/\/dailytalks.org\/?author=1"},"category_info":"<a href=\"https:\/\/dailytalks.org\/?cat=16\" rel=\"category\">Europe<\/a>","tag_info":"Europe","comment_count":"0","_links":{"self":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts\/12464","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=12464"}],"version-history":[{"count":0,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts\/12464\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/media\/12465"}],"wp:attachment":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=12464"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=12464"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=12464"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}